An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine. - NO25530 Papillary Thyroid Cancer

Hoffmann-La Roche0 个研究点目标入组 8 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Hoffmann-La Roche
入组人数: 8

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1. Male or female patients >= 18 years of age
•2. Histologically confirmed papillary thyroid cancer that is metastatic or unresectable
•and for which standard curative or palliative measures do not exist or are no longer
•effective.Patients whose tumors exhibit areas of *other histology* may be
•enrolled, provided the tumor histology remains predominantly papillary.
•Patients whose tumors exhibit *mixed* histology may be discussed with the
•Medical Monitor if there are questions about eligibility.
•3. BRAFV600-positive thyroid cancer tissue, as determined by the Roche-designated
•Central Reference Laboratory using the cobas® 4800 BRAF V600 Mutation Test.
•Testing requires a formalin-fixed paraffin-embedded (FFPE) tumor tissue block or
•unstained sections from such a block. Samples may be either archival or new. Fine
•needle and core needle biopsies will not be accepted.
•4. Must have radioactive iodine resistant disease, defined by any one of the following:
•o lack of RAI uptake on either a low-dose diagnostic or a post-therapy RAI scan in
•the measurable lesion (or lesions) demonstrated previously (without time
•limitation), or
•o radiographic progression of disease within 18 months of last course of RAI
•therapy despite the presence of RAI uptake on the scans performed with that prior
•therapy, or
•o Patient that has exceeded a cumulative activity of at least 600 mCi of radioiodine
•5. Thyroid carcinoma tissue, either archival or recent biopsy must be available for
•submission and review by a central pathology laboratory.
•6. Allowed Prior therapy:
•- Cohort 1: may have received surgery, RAI, and/or standard of care chemotherapy
•(e.g. doxorubicin) [Note: Acceptable prior chemotherapy can be discussed with
•the Sponsor.]
•Cohort 2: may have received surgery, RAI, and standard of care chemotherapy
•(e.g. doxorubicin), and must also have received prior treatment with investigational
•or commercial tyrosine kinase inhibitor with activity against VEGFR2 provided the
•drug is not a specific/selective BRAF or MEK pathway inhibitor. [Note: Acceptable
•prior chemotherapy can be discussed with the Sponsor.]
•7. Must have fully recovered from the effects of any previous therapies.
•8. Radiologic (CT or MRI) evidence of clinically relevant disease progression (as per
•RECIST 1.1) within the preceding 14 months prior to planned first treatment.
•9. Measurable disease (by RECIST Version 1.1 criteria)
•10. ECOG performance status of 0 or 1
•11. Life expectancy > 3 months
•12. Be able to swallow pills
•13. Must have a head CT/MRI to evaluate for CNS metastasis within 28 days prior to
•study drug treatment (Cycle 1 Day 1). Patients with radiographically stable,
•asymptomatic previously treated lesions are eligible provided:
•o Patient has received prior treatment (including radiation), stereotactic radiosurgery, surgical resection) to the
•site(s) of CNS metastatic disease >= 28 days prior to starting study treatment
•o Patient has no requirement for glucocorticoids, and discontinued >= 21 days prior
•to starting study treatment)
•o Patient is not taking anticonvulsants (discontinued at least 3 weeks prior to
•o Patient has no overt evidence of neurological deficit
•14. Prior Surgery (excluding tumor biopsy at baseline for biomarker analysis) must have
•occurred at least 14 days

排除标准

•1. Histological diagnosis other than papillary thyroid carcinoma (PTC), including
•squamous cell variants of PTC or PTC with areas of squamous metaplasia.Patients with anaplastic tumors are not eligible. However, patients whose tumors contain areas of *un-differentiated* or *de-differentiated* histology may enroll provided the original diagnosis was clearly PTC, and the tumor histology remains predominantly papillary at enrollment. Patients whose tumors exhibit mixed histology may be discussed with the Medical Monitor.
•2. Active or untreated CNS metastases 3. History of or known carcinomatous meningitis
•4. Anticipated or ongoing administration of any anti-cancer therapies other than those
•administered in this study
•5. Active squamous cell skin cancer that has not been excised or has not yet adequately
•healed post excision
•6. Pregnant or lactating women
•7. Previous treatments with any commercial or investigational targeted agents that
•specifically and selectively targets the MEK or BRAF pathway
•8. Received any investigational treatment within 28 days prior to start of study treatment
•9. Prior radioactive iodine therapy within 28 days prior to start of study treatment
•10. Chemotherapy or targeted therapy (in case of cohort 2) within 28 days prior to start of
•study treatment
•11. Prior radiotherapy to the only measurable lesion
•12. Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant
•bowel resection that would preclude adequate absorption
•13. QTc >450 msec on screening ECG or history of congenital long QT
•syndrome or uncorrectable electrolytes abnormalities.At least one QTc measurement using Fridericia*s correction (QTcF)
•must be <= 450 msec. Additionally, cases of patients with stable asymptomatic
•conduction delays (e.g., right bundle branch block) with QTc >450 msec may
•be discussed with the Medical Monitor for potential inclusion.
•14. NCI CTCAE Version 4.0 grade 3 hemorrhage within 28 days of starting the study
•15. Any of the following within the 6 months prior to study drug administration:
•myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft,
•symptomatic congestive heart failure, cerebrovascular accident or transient ischemic
•attack, or active pulmonary embolism
•16. Known clinically significant active infection at the time of study treatment start
•17. History of allogeneic bone marrow transplantation or organ transplantation
•18. Other severe, acute or chronic medical or psychiatric condition or laboratory
•abnormality that may increase the risk associated with study participation or study
•drug administration, or may interfere with the interpretation of study results, which in
•the judgment of the investigator would make the patient inappropriate for entry into
•19. Patients with a previous malignancy are excluded except for patients with adequately
•treated basal cell or squamous cell skin cancer, in situ cervical cancer and/or
•curatively treated cancer, from which the patient is currently disease-free, or any
•malignancy from which the patient has been continuously disease-free for at least 5
•years. Also, isolated elevation in PSA in the absence of prostate cancer is allowed
•20. Known HIV positivity or AIDS-related illness, HBV, and active HCV

研究者

发起方

Hoffmann-La Roche

相似试验

进行中（未招募）

不适用

A Study of RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutatioMetastatic or unresectable papillary thyroid cancer positive for BRAF V600 mutation and resistant to radioactive iodine therapyMedDRA version: 14.1Level: LLTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2010-024133-23-ITF. Hoffman-La Roche Ltd.40

进行中（未招募）

不适用

A Study of RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutatioMetastatic or unresectable papillary thyroid cancer positive for BRAFV600 mutation and resistant to radioactive iodine therapyMedDRA version: 15.1Level: LLTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 100000004864

EUCTR2010-024133-23-NLF. Hoffman-La Roche Ltd.40

进行中（未招募）

不适用

Study of the clinical activity and safety of vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia carrying the BRAF-V600E mutatioHairy cell leukemia (HCL)carrying the BRAF-V600 mutationMedDRA version: 14.1Level: PTClassification code 10019053Term: Hairy cell leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-005487-13-ITIVERSITA' DEGLI STUDI DI PERUGIA

进行中（未招募）

1 期

An open-label study in patients with advanced cancer.HLA-A*0201 positive patients with advanced antigen-positive cancer with a histologic diagnosis of Non small cell lung carcinoma (NSCLC), melanoma, urothelial carcinoma, or synovial sarcoma with antigen positivity for NY-ESO-1 and/or LAGE-1AMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10025665Term: Malignant melanoma of skin stage unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-002243-15-GBImmunocore Ltd.63

进行中（未招募）

1 期

EUCTR2018-003172-12-ITKymab Limited412